{"log_id": 668156409198773055, "direction": 0, "words_result_num": 35, "words_result": [{"probability": {"variance": 3e-06, "average": 0.999355, "min": 0.991856}, "location": {"width": 657, "top": 129, "height": 58, "left": 175}, "words": "那西普治疗前、治疗中和治疗后,必须对患者的感染情况进行评价"}, {"probability": {"variance": 0, "average": 0.999989, "min": 0.999989}, "location": {"width": 32, "top": 120, "height": 29, "left": 1165}, "words": "管"}, {"probability": {"variance": 4e-06, "average": 0.99881, "min": 0.989313}, "location": {"width": 809, "top": 168, "height": 68, "left": 222}, "words": "曾有使用依那西普发生严重感染、脓毒血症、结核病和机会致病菌感染(包括侵袭"}, {"probability": {"variance": 0, "average": 0.992297, "min": 0.992297}, "location": {"width": 56, "top": 160, "height": 32, "left": 1153}, "words": "文"}, {"probability": {"variance": 0, "average": 0.998994, "min": 0.998994}, "location": {"width": 35, "top": 203, "height": 31, "left": 1171}, "words": "章"}, {"probability": {"variance": 7e-06, "average": 0.998663, "min": 0.988079}, "location": {"width": 853, "top": 219, "height": 67, "left": 178}, "words": "性真菌感染)的报告(参见“不良反应”)。这些感染是由细菌、分枝杆菌、真菌和病毒"}, {"probability": {"variance": 1.1e-05, "average": 0.998643, "min": 0.983562}, "location": {"width": 853, "top": 269, "height": 68, "left": 178}, "words": "引起的。在某些情况下,由于真菌和其他机会致病菌不能被识别导致治疗延误,有时导"}, {"probability": {"variance": 0.004356, "average": 0.984617, "min": 0.612088}, "location": {"width": 857, "top": 319, "height": 69, "left": 178}, "words": "致死亡。在很多报告中,患者也同时使用包括免疫抑制剂在内的药物治疗。在评估患者"}, {"probability": {"variance": 0, "average": 0.999312, "min": 0.99722}, "location": {"width": 720, "top": 375, "height": 63, "left": 180}, "words": "感染情况时,相关机会致病菌对患者的风险也应考虑(如地方性真菌病)"}, {"probability": {"variance": 4.4e-05, "average": 0.998275, "min": 0.959152}, "location": {"width": 811, "top": 419, "height": 65, "left": 226}, "words": "需要对在依那西普治疗过程中出现新发感染的患者进行严密监测。如果患者出现严"}, {"probability": {"variance": 3.7e-05, "average": 0.997904, "min": 0.962727}, "location": {"width": 856, "top": 469, "height": 65, "left": 182}, "words": "重感染必须停止使用依那西普。复发性或慢性感染的患者或存在可能导致患者易受感染"}, {"probability": {"variance": 6e-06, "average": 0.998553, "min": 0.991392}, "location": {"width": 860, "top": 516, "height": 68, "left": 182}, "words": "的潜在条件(如晚期糖尿病或糖尿病控制不良),当考虑使用依那西普治疗时,应谨慎"}, {"probability": {"variance": 0, "average": 0.999716, "min": 0.999467}, "location": {"width": 47, "top": 603, "height": 27, "left": 184}, "words": "使用"}, {"probability": {"variance": 9e-06, "average": 0.996535, "min": 0.992113}, "location": {"width": 136, "top": 650, "height": 29, "left": 185}, "words": "结核病(TB)"}, {"probability": {"variance": 0.000123, "average": 0.994561, "min": 0.951896}, "location": {"width": 817, "top": 665, "height": 65, "left": 230}, "words": "已有报告使用TNF拮抗剂(包括依那西普)的患者出现结核病,包括弥散性结核"}, {"probability": {"variance": 3e-06, "average": 0.998833, "min": 0.990237}, "location": {"width": 752, "top": 719, "height": 61, "left": 186}, "words": "和肺外表现。结核病的出现可能是由于潜伏性结核感染的再活化或新的感染"}, {"probability": {"variance": 2e-06, "average": 0.999155, "min": 0.992015}, "location": {"width": 819, "top": 763, "height": 65, "left": 232}, "words": "在开始使用依那西普治疗前,必须对结核病风险高的患者进行活动性或潜伏性结核"}, {"probability": {"variance": 2e-06, "average": 0.999026, "min": 0.991866}, "location": {"width": 863, "top": 812, "height": 66, "left": 187}, "words": "感染的评估。该评估包括结核病患者的个人信息及详细医疗史、以往与结核病人的接触"}, {"probability": {"variance": 0.005053, "average": 0.985159, "min": 0.556965}, "location": {"width": 864, "top": 861, "height": 64, "left": 188}, "words": "史和以往和/或目前的免疫抑制治疗法。所有患者需进行恰当的筛选试验,例如结合菌"}, {"probability": {"variance": 0.000881, "average": 0.992499, "min": 0.832294}, "location": {"width": 865, "top": 910, "height": 64, "left": 189}, "words": "素皮肤试验及胸部X线检查(可以参考当地推荐的方法)。处方医生应注意结合菌素皮"}, {"probability": {"variance": 1e-06, "average": 0.999209, "min": 0.995218}, "location": {"width": 714, "top": 965, "height": 58, "left": 189}, "words": "肤试验出现假阴性的结果,特别是那些患有严重疾病或免疫缺陷的患者"}, {"probability": {"variance": 1e-06, "average": 0.999327, "min": 0.993082}, "location": {"width": 818, "top": 1009, "height": 61, "left": 237}, "words": "如果患者确诊为活动性结核感染,则禁止使用依那西普治疗。在依那西普开始治疗"}, {"probability": {"variance": 5e-06, "average": 0.999109, "min": 0.98788}, "location": {"width": 869, "top": 1058, "height": 60, "left": 191}, "words": "前,必须预防潜伏性结核感染。有些治疗前潜伏性结核感染检测为阴性的患者,使用依"}, {"probability": {"variance": 5.8e-05, "average": 0.998183, "min": 0.952152}, "location": {"width": 868, "top": 1105, "height": 62, "left": 191}, "words": "那西普后发展为活动性结核感染。使用依那西普过程中医生应监测患者有活动性结核感"}, {"probability": {"variance": 8.6e-05, "average": 0.997832, "min": 0.942572}, "location": {"width": 860, "top": 1154, "height": 62, "left": 190}, "words": "染的体征和症状,包括那些潜伏性感染检测阴性的患者。并应参考适用的当地治疗指南"}, {"probability": {"variance": 2e-06, "average": 0.998968, "min": 0.992582}, "location": {"width": 870, "top": 1202, "height": 63, "left": 191}, "words": "如果患者确诊为潜伏性结核病,则在开始使用依那西普前必须按照当地推荐的方法进行"}, {"probability": {"variance": 1.7e-05, "average": 0.998196, "min": 0.98342}, "location": {"width": 869, "top": 1253, "height": 60, "left": 193}, "words": "抗结核治疗。在这种情况下,应慎重考虑使用依那西普治疗的受益/风险平衡。类风湿"}, {"probability": {"variance": 0, "average": 0.999371, "min": 0.998125}, "location": {"width": 352, "top": 1320, "height": 41, "left": 193}, "words": "关节炎患者结核感染的几率会更高"}, {"probability": {"variance": 1.5e-05, "average": 0.998137, "min": 0.978421}, "location": {"width": 823, "top": 1352, "height": 57, "left": 241}, "words": "应告知患者在使用依那西普治疗期间或治疗以后,患者若出现结核病(例如,持续"}, {"probability": {"variance": 2e-06, "average": 0.999019, "min": 0.993722}, "location": {"width": 588, "top": 1409, "height": 50, "left": 195}, "words": "性咳嗽、体重减轻和低热)的体征症状均应寻求医学指导"}, {"probability": {"variance": 9e-06, "average": 0.997901, "min": 0.990784}, "location": {"width": 189, "top": 1472, "height": 34, "left": 197}, "words": "乙型肝炎病毒激活"}, {"probability": {"variance": 0.00963, "average": 0.975582, "min": 0.532081}, "location": {"width": 824, "top": 1500, "height": 55, "left": 241}, "words": "曾有慢性乙型肝炎病毒的携带者接受包括依那西普在内的TNVF抑制剂治疗时出现"}, {"probability": {"variance": 0.000773, "average": 0.992594, "min": 0.822143}, "location": {"width": 865, "top": 1548, "height": 57, "left": 199}, "words": "乙肝病毒(HBV)激活的报告。有HBV感染风险的患者在开始抗-TNF治疗前,必须对"}, {"probability": {"variance": 0.000215, "average": 0.992726, "min": 0.954093}, "location": {"width": 176, "top": 1601, "height": 29, "left": 810}, "words": "第10页共31页"}, {"probability": {"variance": 0.000164, "average": 0.989988, "min": 0.961085}, "location": {"width": 161, "top": 1624, "height": 25, "left": 199}, "words": "版本号:20090118"}], "language": 3}